There is much debate surrounding the suitability and utility of different prognostic markers in prostate cancer. PSA doubling time (PSADT) has become an important marker in predicting the response to salvage radiotherapy and progression to metastatic disease in men with biochemical failure following local therapy. The methods of calculating PSADT and its use as a prognostic marker are discussed in this review by James Eastham.